Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2022 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
March 01, 2022 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
February 28, 2022 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in...
February 22, 2022 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
February 03, 2022 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
January 11, 2022 14:15 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers First Patient Dosed in Global Phase...
January 04, 2022 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted...
November 24, 2021 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
November 10, 2021 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...
November 08, 2021 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right